Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia (CLL).

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select first-line therapy for treatment-naive CLL/SLL, taking into consideration the regimen’s toxicity profile, prognostic variables, comorbidities, duration, and patient preference
  • Plan an individual treatment approach including sequence of therapy for relapsed/refractory CLL/SLL to optimize clinical benefit and quality of life in alignment with patient preference
  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents with the similar molecular target 
  • Evaluate emerging strategies such as measurable residual disease (MRD; often referred to as minimal residual disease), non-covalent reversible BTKis, allogeneic hematopoietic cell transplant (HCT), and chimeric antigen receptor (CAR) T-cell therapy
Additional information

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

Course summary
Available credit: 
  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation
Course opens: 
Course expires: 

Danielle M. Brander, MD
Assistant Professor of Medicine
Director, CLL and Lymphoma Program
Duke Cancer Institute
Duke University School of Medicine
Durham, North Carolina

Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Deborah Stephens, DO
Associate Professor
Division of Hematology
Department of Internal Medicine
University of North Carolina
Chapel Hill, North Carolina


NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Danielle M. Brander, MD
AbbVie, Inc.: Consultant/Advisor/Speaker; Grant/Research Support
ArQule/Merck: Consultant/Advisor/Speaker; Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Grant/Research Support
CATO SMS: Grant/Research Support
DTRM: Grant/Research Support
Genentech, Inc.: Consultant/Advisor/Speaker; Grant/Research Support
Juno/Celgene/Bristol Myers Squibb: Grant/Research Support
Newave Inc.: Grant/Research Support
Pfizer Inc.: Consultant/Advisor/Speaker; Grant/Research Support
Pharmacyclics: Consultant/Advisor/Speaker; Grant/Research Support
TG Therapeutics, Inc.: Consultant/Advisor/Speaker; Grant/Research Support

Brian Hill, MD, PhD
AbbVie, Inc.: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
Bristol Myers Squibb: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Kite Pharma: Consultant/Advisor/Speaker
Novartis Pharmaceuticals Corporation: Consultant/Advisor/Speaker

Deborah Stephens, DO
AbbVie, Inc.: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker; Grant/Research Support
BeiGene: Consultant/Advisor/Speaker
Bristol Myers Squibb/Celgene: Consultant/Advisor/Speaker
Eli Lilly and Company: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker
Novartis Pharmaceuticals Corporation: Grant/Research Support

NCCN and CCO Staff Disclosures

None of the planners/managers for this educational activity has relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 2.0 contact hours.

NCCN designates this application-based continuing education activity for 2.0 contact hours (0.20 CEUs) of continuing education credit. UAN: JA4008196-0000-23-135-H01-P

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until December 21, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing